GLP-1s and Depression: What the Research Actually Says

Based on the best current evidence, GLP-1 medications do not appear to cause depression. This question arose in 2023 when European regulators began investigating a small number of reports of suicidal thoughts among people taking GLP-1 drugs, prompting headlines and understandable worry. Since then, much larger and more rigorous studies have examined the question, and the reassuring picture has held.

The most-cited analysis, published in Nature Medicine (2024) by researchers using electronic health records of more than 3 million patients, found no increased risk of suicidal ideation with semaglutide compared with other treatments — and in some comparisons, a *lower* risk. The US FDA conducted its own review of post-marketing data in 2024 and stated it found no clear evidence that GLP-1 medications cause suicidal thoughts or actions.

It's worth understanding why isolated reports can be misleading. People taking GLP-1s for obesity or diabetes already have higher baseline rates of depression than the general population, so some depression will occur in this group regardless of the medication. Distinguishing coincidence from causation requires large controlled studies — exactly the kind that have now been done. The current scientific consensus is that GLP-1s are not a cause of depression, though monitoring remains sensible, as it does with any medication.

The latest research on GLP-1s and mental health is largely reassuring, and in places even suggests possible benefit. Beyond the 3-million-patient Nature Medicine (2024) study finding no increased suicidal-ideation risk, several other lines of evidence point the same direction.

Some studies exploring the anti-inflammatory and metabolic effects of GLP-1 drugs have raised the possibility that they could *improve* mood in certain people. Because obesity, diabetes, and depression share links through inflammation and metabolic dysfunction, treating the metabolic condition may indirectly help mood. A few analyses have reported modestly lower rates of depression diagnoses among GLP-1 users, though this is an emerging and not-yet-settled area.

Regulatory bodies have weighed in. After its review, the FDA did not add a causal warning for depression or suicidality specific to a GLP-1 effect. European regulators similarly concluded the available evidence did not support a causal link.

An important nuance: the clinical trials that led to approval, like STEP and SURMOUNT, generally excluded people with recent severe depression or suicidal history, so the trial data speaks mostly to people without active severe mental illness. This is why ongoing real-world monitoring matters, and why anyone with a significant psychiatric history should have that conversation with their prescriber. Overall, though, the weight of current evidence is that GLP-1s are not driving depression.

Yes — significant, rapid weight loss can affect mood in complex ways that are separate from any direct drug effect on the brain. This is one of the more nuanced parts of the picture, because the *experience* of dramatic change can be emotionally destabilizing even when the medication itself isn't the culprit.

Many people feel better as they lose weight: improved energy, mobility, confidence, and relief from weight-related health worries can lift mood. But others encounter unexpected emotional challenges. Losing a large amount of weight can trigger an identity shift — questions about who you are, changed relationships, and even grief for a former self. Some people used food as a primary source of comfort and coping, and when the [food noise quiets](/blog/food-noise-on-glp1-what-it-is-and-why-it-quiets) and eating changes, they can feel unexpectedly adrift without that coping tool. We explore this more in our piece on the [GLP-1 identity crisis](/blog/glp1-identity-crisis-who-are-you-after-weight-loss).

Nutrition plays a role too. If appetite suppression leads to very low food intake, deficiencies in nutrients that support brain health, low blood sugar, or simple under-fuelling can leave you feeling flat, irritable, or foggy. Dehydration and poor sleep compound this. This is a good reason to prioritize adequate [protein](/blog/protein-on-glp1-how-much-you-really-need) and balanced nutrition even when you're not hungry. The takeaway: if your mood dips on a GLP-1, the cause is often these surrounding factors rather than a toxic effect of the drug — and most are addressable.

For women going through menopause, the mood picture is worth special attention — not because GLP-1s become dangerous, but because menopause itself independently affects mood and the two experiences overlap. Falling estrogen during perimenopause disrupts serotonin and other mood-regulating systems, making women more vulnerable to [anxiety](/blog/menopause-anxiety-why-it-spikes-and-how-to-cope) and low mood during this life stage.

So a woman on a GLP-1 during menopause who notices her mood dipping is navigating two things at once. It's easy to blame the medication, when the hormonal transition may be the larger driver. Untangling the causes matters because the solutions differ: menopause-related mood changes may respond to HRT, sleep support, or targeted therapy, while GLP-1-related factors might call for better nutrition or emotional support around body changes.

Encouragingly, some emerging research on GLP-1s in this population suggests neutral-to-positive effects on mood and wellbeing, likely tied to improvements in weight, sleep, and metabolic health — all of which are strained in menopause. Our overview of [GLP-1s, mood and menopause](/blog/glp1-mood-mental-health-menopause-what-research-shows) goes deeper.

The practical message for midlife women: monitor your mood, don't assume any dip is 'just the medication,' and give your clinician the full picture — both the GLP-1 and where you are in the menopause transition — so you get help aimed at the real cause.

Even though the research is reassuring, it's wise to monitor your mental health on any medication and know the warning signs that deserve attention. Watch for a persistent low mood lasting two weeks or more, loss of interest or pleasure in things you normally enjoy, changes in sleep or appetite beyond what the medication explains, feelings of hopelessness or worthlessness, difficulty functioning at work or home, or increased irritability and withdrawal from people.

Most importantly, take any thoughts of self-harm or suicide seriously and seek help immediately — the same day. These thoughts are a symptom, they are treatable, and reaching out is a sign of strength, not failure. In the US you can call or text 988 (the Suicide and Crisis Lifeline) any time; elsewhere, contact your local emergency services or a crisis line.

Be especially attentive if you have a personal history of depression, anxiety, or suicidal thoughts, since the approval trials didn't study people with recent severe mental illness. Tell your prescriber about that history before starting, and keep them in the loop as you go.

Finally, don't tough it out alone. Whether a mood change stems from the medication, rapid weight loss, menopause, or life circumstances, effective help exists — from therapy and lifestyle changes to medication adjustments. If your mood shifts meaningfully after starting a GLP-1, tell your clinician rather than quietly stopping the medication, so you can figure out the cause together. This article is educational and isn't a substitute for personal medical care.